Skip to main content

Table 5 Multivariate analysis for the predictive value of PTEN deletion, MGMT methylation and EGFR amplification in GBM IDH wildtype

From: Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

 

Median Survival (MS-months)

N

Multivariate analysisa

Hazard ratio

95% Cl

p-Value

GBM IDH-wildtype

CRT

16.0

104

0.053

0.029–0.098

< 0.001

RT

6.0

104

0.181

0.105–0.314

< 0.001

None

2.0

18

 

Reference

 

RT

 PTEN

  Deleted

7.0

74

0.74

0.45–1.24

0.258

  Non-deleted

6.0

20

 

Reference

 

 MGMT

  Methylated

7.0

24

1.09

0.67–1.78

0.733

  Unmethylated

6.0

70

 

Reference

 

 EGFR

  Amplified

9.0

39

0.56

0.36–0.88

0.011

  Non-amplified

6.0

55

 

Reference

 

CRT

 PTEN

  Deleted

14.0

84

1.68

0.40–7.15

0.481

  Non-deleted

14.0

5

 

Reference

 

 MGMT

  Methylated

32.0

20

0.34

0.17–0.69

0.003

  Unmethylated

14.0

69

 

Reference

 

EGFR

  Amplified

15.0

32

0.88

0.54–1.43

0.596

  Non-amplified

14.0

57

 

Reference

 
  1. aMultivariate analysis was performed controlling the following independent variables: age and gender. RT Radiotherapy, CRT Chemo-radiotherapy
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us